Trial
NCT02547220
A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Shire
Collaborators
—
Condition
Acute Antibody-Mediated Rejection (AMR)
Intervention
Cinryze®
Why stopped
Following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-13